Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Pai

Showing results (241-250 of 360) with videos related to

Pageof 36
Sort By:
Therapeutic Drug Monitoring|March 31, 2026
Translating Antibiotic Concentrations From Whole Blood to Plasma in Volumetric Absorptive Microsampling Applications: Letter to the EditorMy Tuyen T Nguyen, Bo Wen, Kevin J Downes, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic FibrosisRyan L Crass, Tamara Al Naimi, Bo Wen, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein bindingJill M Butterfield, Nimish Patel, Manjunath P Pai, et al.
Current Medical Research and Opinion|May 24, 2007
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysisHua Chen, Katie J Suda, Robin S Turpin, et al.
Diagnostic Microbiology and Infectious Disease|April 29, 2017
Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot studyD M Martirosov, M R Bidell, M P Pai, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2002
Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faeciumManjunath P Pai, Keith A Rodvold, Paul C Schreckenberger, et al.
International Journal of STD & AIDS|June 1, 2012
Simultaneous triple point-of-care testing for HIV, syphilis and hepatitis B virus to prevent mother-to-child transmission in IndiaN P Pai, J Kurji, A Singam, et al.
Lupus|June 29, 2014
Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activityX-Y Li, P Xiao, H-B Xiao, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Pageof 36

Showing results (241-250 of 360) with videos related to

Sort By:
Pageof 36
Therapeutic Drug Monitoring|March 31, 2026
Translating Antibiotic Concentrations From Whole Blood to Plasma in Volumetric Absorptive Microsampling Applications: Letter to the EditorMy Tuyen T Nguyen, Bo Wen, Kevin J Downes, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic FibrosisRyan L Crass, Tamara Al Naimi, Bo Wen, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein bindingJill M Butterfield, Nimish Patel, Manjunath P Pai, et al.
Current Medical Research and Opinion|May 24, 2007
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysisHua Chen, Katie J Suda, Robin S Turpin, et al.
Diagnostic Microbiology and Infectious Disease|April 29, 2017
Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot studyD M Martirosov, M R Bidell, M P Pai, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2002
Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faeciumManjunath P Pai, Keith A Rodvold, Paul C Schreckenberger, et al.
International Journal of STD & AIDS|June 1, 2012
Simultaneous triple point-of-care testing for HIV, syphilis and hepatitis B virus to prevent mother-to-child transmission in IndiaN P Pai, J Kurji, A Singam, et al.
Lupus|June 29, 2014
Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activityX-Y Li, P Xiao, H-B Xiao, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Pageof 36